XML 81 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related-party Transactions (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Feb. 01, 2017
Jul. 31, 2016
Dec. 31, 2017
Celegene Collaborative Arrangement      
Related Party Transaction [Line Items]      
Non-refundable upfront payment received for research agreement   $ 225.0  
Series B-1 Convertible Preferred Stock      
Related Party Transaction [Line Items]      
Issuances of convertible preferred stock (in shares)     10,448,100
Series B-1 Convertible Preferred Stock | Celegene Collaborative Arrangement      
Related Party Transaction [Line Items]      
Issuances of convertible preferred stock (in shares)   10,448,100  
Issuances of convertible preferred stock   $ 36.1  
IPO      
Related Party Transaction [Line Items]      
Stock converted upon completion of IPO (in shares) 22,283,690    
Proceeds from IPO, net of discounts, commissions, and other offering expenses $ 106.4    
Celgene Corporation | Celgene Collaboration Agreement | Celegene Collaborative Arrangement      
Related Party Transaction [Line Items]      
Non-refundable upfront payment received for research agreement   $ 225.0  
Celgene Corporation | Celgene Collaboration Agreement | Series B-1 Convertible Preferred Stock | Celegene Collaborative Arrangement      
Related Party Transaction [Line Items]      
Issuances of convertible preferred stock (in shares)   10,448,100  
Issuances of convertible preferred stock   $ 36.1  
Celgene Corporation | IPO | Celgene Collaboration Agreement | Common Stock      
Related Party Transaction [Line Items]      
Stock converted upon completion of IPO (in shares) 2,831,463    
Affiliated Entity | Celgene Corporation | IPO | Celgene Collaboration Agreement | Common Stock      
Related Party Transaction [Line Items]      
Sale of stock, number of shares issued (in shares) 625,000    
Sale of stock, price per share (USD per share) $ 16.00    
Proceeds from IPO, net of discounts, commissions, and other offering expenses $ 10.0